Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up
- PMID: 8578851
- DOI: 10.1016/0264-410x(95)00064-8
Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up
Abstract
A two-dose vaccination program against measles, mumps, and rubella (MMR) viruses was started in Finland in 1982. In this program the trivalent MMR-II vaccine (MSD, USA) was offered to children at the ages of 14-18 months and 6 years followed by revaccination 4-5 years later. The vaccination coverage has been high (97%) and MMR infections have practically been eliminated in the Finnish population. In a serological follow-up program sequential serum samples were obtained from 254 children (127 14-18-month-old vaccinees and 127 6-year-old vaccinees) during a 9-year follow-up period. Anti-mumps virus antibody titers were determined by enzyme immunoassay using purified whole mumps viruses as the antigen. In seronegative (n = 120) 14-18-month-old vaccinees the seroconversion rate was 86% (geometric mean titer 1/1670 +/- 1/270). The antibody levels fell rapidly (significance p < 0.01) within the first year of follow-up (mean titer 1/1080 +/- 1/190), but remained relatively stable in subsequent years. After revaccination the seropositivity rate was 95% (mean titer 1/2310 +/- 1/260) and declined more slowly thereafter to 86% (mean titer 1/1510 +/- 1/210) at year 9 of follow-up. The mean antibody titer was significantly (p < 0.05) higher 4 years after the second MMR vaccination when compared with the corresponding time point after the first vaccination. In 6-year-old seronegative vaccinees the increase and decay of anti-mumps virus antibodies after the first MMR vaccination was similar to that seen in the group of younger vaccinees. A two-dose MMR vaccination protocol resulted in a high mumps immunity level in the vaccinated population.
Similar articles
-
Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.Vaccine. 2000 Jul 15;18(27):3106-12. doi: 10.1016/s0264-410x(00)00139-0. Vaccine. 2000. PMID: 10856790
-
Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.Vaccine. 1995 Nov;13(16):1611-6. doi: 10.1016/0264-410x(95)00098-l. Vaccine. 1995. PMID: 8578850
-
Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.Vaccine. 2000 Jan 31;18(14):1382-92. doi: 10.1016/s0264-410x(99)00397-7. Vaccine. 2000. PMID: 10618536 Clinical Trial.
-
[Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].Ugeskr Laeger. 1992 Jul 13;154(29):2008-13. Ugeskr Laeger. 1992. PMID: 1509566 Review. Danish.
-
Rational use of measles, mumps and rubella (MMR) vaccine.Drugs. 1993 May;45(5):677-83. doi: 10.2165/00003495-199345050-00005. Drugs. 1993. PMID: 7686463 Review.
Cited by
-
Factors That Influence the Immune Response to Vaccination.Clin Microbiol Rev. 2019 Mar 13;32(2):e00084-18. doi: 10.1128/CMR.00084-18. Print 2019 Mar 20. Clin Microbiol Rev. 2019. PMID: 30867162 Free PMC article. Review.
-
The Xs and Y of immune responses to viral vaccines.Lancet Infect Dis. 2010 May;10(5):338-49. doi: 10.1016/S1473-3099(10)70049-9. Lancet Infect Dis. 2010. PMID: 20417416 Free PMC article. Review.
-
Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?Epidemiol Infect. 2013 Mar;141(3):651-66. doi: 10.1017/S0950268812001136. Epub 2012 Jun 12. Epidemiol Infect. 2013. PMID: 22687578 Free PMC article.
-
Mumps and the UK epidemic 2005.BMJ. 2005 May 14;330(7500):1132-5. doi: 10.1136/bmj.330.7500.1132. BMJ. 2005. PMID: 15891229 Free PMC article. Review. No abstract available.
-
Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.J Virol. 2012 Jan;86(1):615-20. doi: 10.1128/JVI.06125-11. Epub 2011 Nov 9. J Virol. 2012. PMID: 22072778 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources